Haemonetics reported its third quarter (Q3) fiscal 2026 results, highlighting growth across key business units and continued focus on value creation. For Q3 FY26, Plasma revenue reached USD 138.9 million, representing a 3.5% increase. The Apheresis business unit generated USD 56.6 million in revenue, with growth of 2.1% for the period. The company continued its share buyback program, repurchasing approximately 360,000 shares of HAE common stock subsequent to quarter-end. Haemonetics emphasized its strategy of translating earnings into cash and maintaining margin expansion, despite portfolio transitions during the previous year, including the divestiture of its Whole Blood product line in January 2025 and the exit of certain liquid solution products. Management reaffirmed its focus on delivering earnings growth and creating additional avenues for value creation. The company also noted that adjusted net income and adjusted earnings per diluted share exclude the tax impact of certain items, with tax adjustments calculated based on the jurisdictions where pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of proceeds from the sale of property, plant and equipment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.